Skip to main content
Erschienen in: Journal of Neural Transmission 4/2024

24.01.2024 | Neurology and Preclinical Neurological Studies - Review Article

Mild cognitive impairment in Huntington’s disease: challenges and outlooks

verfasst von: Kurt A. Jellinger

Erschienen in: Journal of Neural Transmission | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Although Huntington's disease (HD) has classically been viewed as an autosomal-dominant inherited neurodegenerative motor disorder, cognitive and/or behavioral changes are predominant and often an early manifestation of disease. About 40% of individuals in the presymptomatic period of HD meet the criteria for mild cognitive impairment, later progressing to dementia. The heterogenous spectrum of cognitive decline is characterized by deficits across multiple domains, particularly executive dysfunctions, but the underlying pathogenic mechanisms are still poorly understood. Investigating the pathophysiology of cognitive changes may give insight into important and early neurodegenerative events. Multimodal imaging revealed circuit-wide gray and white matter degenerative processes in several key brain regions, affecting prefronto-striatal/cortico-basal ganglia circuits and many other functional brain networks. Studies in transgenic animal models indicated early synaptic dysfunction, deficient neurotrophic transport and other molecular changes contributing to neuronal death. Synaptopathy within the cerebral cortex, striatum and hippocampus may be particularly important in mediating cognitive and neuropsychiatric manifestations of HD, although many other neuronal systems are involved. The interaction of mutant huntingtin protein (mHTT) with tau and its implication for cognitive impairment in HD is a matter of discussion. Further neuroimaging and neuropathological studies are warranted to better elucidate early pathophysiological mechanisms and to develop validated biomarkers to detect patients' cognitive status during the early stages of the condition significantly to implement effective preventing or management strategies.
Literatur
Zurück zum Zitat Adler CH, Beach TG (2010) Variability of diffuse plaques and amyloid angiopathy in Parkinson’s disease with mild cognitive impairment (Correspondence). Acta Neuropathol 120:831–832CrossRef Adler CH, Beach TG (2010) Variability of diffuse plaques and amyloid angiopathy in Parkinson’s disease with mild cognitive impairment (Correspondence). Acta Neuropathol 120:831–832CrossRef
Zurück zum Zitat Adler CH, Caviness JN, Sabbagh MN, Shill HA, Connor DJ, Sue L, Evidente VG, Driver-Dunckley E, Beach TG (2010) Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol 120:827–828PubMedPubMedCentralCrossRef Adler CH, Caviness JN, Sabbagh MN, Shill HA, Connor DJ, Sue L, Evidente VG, Driver-Dunckley E, Beach TG (2010) Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol 120:827–828PubMedPubMedCentralCrossRef
Zurück zum Zitat Aldaz T, Nigro P, Sánchez-Gómez A, Painous C, Planellas L, Santacruz P, Cámara A, Compta Y, Valldeoriola F, Martí MJ, Muñoz E (2019) Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease. J Neurol 266:1340–1350PubMedCrossRef Aldaz T, Nigro P, Sánchez-Gómez A, Painous C, Planellas L, Santacruz P, Cámara A, Compta Y, Valldeoriola F, Martí MJ, Muñoz E (2019) Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease. J Neurol 266:1340–1350PubMedCrossRef
Zurück zum Zitat Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Dadarao Chakole R, Nemade LS, Kishor Kale N, Borah S, Shrikant Deokar S, Behera A, Dhawal Bhandari D, Gaikwad N, Kalam Azad A, Ghosh A (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis -an updated review. Mitochondrion 71:83–92PubMedCrossRef Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Dadarao Chakole R, Nemade LS, Kishor Kale N, Borah S, Shrikant Deokar S, Behera A, Dhawal Bhandari D, Gaikwad N, Kalam Azad A, Ghosh A (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis -an updated review. Mitochondrion 71:83–92PubMedCrossRef
Zurück zum Zitat Andrews SC, Langbehn DR, Craufurd D, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Stout JC (2021) Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington’s disease. Psychol Med 51:1338–1344PubMedCrossRef Andrews SC, Langbehn DR, Craufurd D, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Stout JC (2021) Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington’s disease. Psychol Med 51:1338–1344PubMedCrossRef
Zurück zum Zitat Aracil-Bolaños I, Martínez-Horta S, González-de-Echávarri JM, Sampedro F, Pérez-Pérez J, Horta-Barba A, Campolongo A, Izquierdo C, Gómez-Ansón B, Pagonabarraga J, Kulisevsky J (2022) Structure and dynamics of large-scale cognitive networks in Huntington’s disease. Mov Disord 37:343–353PubMedCrossRef Aracil-Bolaños I, Martínez-Horta S, González-de-Echávarri JM, Sampedro F, Pérez-Pérez J, Horta-Barba A, Campolongo A, Izquierdo C, Gómez-Ansón B, Pagonabarraga J, Kulisevsky J (2022) Structure and dynamics of large-scale cognitive networks in Huntington’s disease. Mov Disord 37:343–353PubMedCrossRef
Zurück zum Zitat Baake V, Reijntjes R, Dumas EM, Thompson JC, Roos RAC (2017) Cognitive decline in Huntington’s disease expansion gene carriers. Cortex 95:51–62PubMedCrossRef Baake V, Reijntjes R, Dumas EM, Thompson JC, Roos RAC (2017) Cognitive decline in Huntington’s disease expansion gene carriers. Cortex 95:51–62PubMedCrossRef
Zurück zum Zitat Barry J, Bui MTN, Levine MS, Cepeda C (2022) Synaptic pathology in Huntington’s disease: beyond the corticostriatal pathway. Neurobiol Dis 162:105574PubMedCrossRef Barry J, Bui MTN, Levine MS, Cepeda C (2022) Synaptic pathology in Huntington’s disease: beyond the corticostriatal pathway. Neurobiol Dis 162:105574PubMedCrossRef
Zurück zum Zitat Bessi V, Mazzeo S, Bagnoli S, Giacomucci G, Ingannato A, Ferrari C, Padiglioni S, Franchi V, Sorbi S, Nacmias B (2021) The effect of CAG repeats within the non-pathological range in the HTT gene on cognitive functions in patients with subjective cognitive decline and mild cognitive impairment. Diagnostics (Basel) 11:1051PubMedCrossRef Bessi V, Mazzeo S, Bagnoli S, Giacomucci G, Ingannato A, Ferrari C, Padiglioni S, Franchi V, Sorbi S, Nacmias B (2021) The effect of CAG repeats within the non-pathological range in the HTT gene on cognitive functions in patients with subjective cognitive decline and mild cognitive impairment. Diagnostics (Basel) 11:1051PubMedCrossRef
Zurück zum Zitat Callahan JW, Abercrombie ED (2011) In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-length (YAC128) transgenic mouse models of Huntington’s disease. Front Syst Neurosci 5:61PubMedPubMedCentralCrossRef Callahan JW, Abercrombie ED (2011) In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-length (YAC128) transgenic mouse models of Huntington’s disease. Front Syst Neurosci 5:61PubMedPubMedCentralCrossRef
Zurück zum Zitat Cavallo M, Sergi A, Pagani M (2022) Cognitive and social cognition deficits in Huntington’s disease differ between the prodromal and the manifest stages of the condition: a scoping review of recent evidence. Br J Clin Psychol 61:214–241PubMedCrossRef Cavallo M, Sergi A, Pagani M (2022) Cognitive and social cognition deficits in Huntington’s disease differ between the prodromal and the manifest stages of the condition: a scoping review of recent evidence. Br J Clin Psychol 61:214–241PubMedCrossRef
Zurück zum Zitat Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH (2007) Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 22:1272–1277PubMedCrossRef Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH (2007) Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 22:1272–1277PubMedCrossRef
Zurück zum Zitat Cepeda C, Hurst RS, Calvert CR, Hernández-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease. J Neurosci 23:961–969PubMedPubMedCentralCrossRef Cepeda C, Hurst RS, Calvert CR, Hernández-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease. J Neurosci 23:961–969PubMedPubMedCentralCrossRef
Zurück zum Zitat Chan ST, Mercaldo ND, Ravina B, Hersch SM, Rosas HD (2021) Association of dilated perivascular spaces and disease severity in patients with Huntington disease. Neurology 96:e890–e894PubMedPubMedCentralCrossRef Chan ST, Mercaldo ND, Ravina B, Hersch SM, Rosas HD (2021) Association of dilated perivascular spaces and disease severity in patients with Huntington disease. Neurology 96:e890–e894PubMedPubMedCentralCrossRef
Zurück zum Zitat Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F (2006) Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 47:215–222PubMed Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F (2006) Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 47:215–222PubMed
Zurück zum Zitat Coppen EM, Grond JV, Hafkemeijer A, Barkey Wolf JJH, Roos RAC (2018a) Structural and functional changes of the visual cortex in early Huntington’s disease. Hum Brain Mapp 39:4776–4786PubMedPubMedCentralCrossRef Coppen EM, Grond JV, Hafkemeijer A, Barkey Wolf JJH, Roos RAC (2018a) Structural and functional changes of the visual cortex in early Huntington’s disease. Hum Brain Mapp 39:4776–4786PubMedPubMedCentralCrossRef
Zurück zum Zitat Coppen EM, van der Grond J, Hart EP, Lakke E, Roos RAC (2018b) The visual cortex and visual cognition in Huntington’s disease: an overview of current literature. Behav Brain Res 351:63–74PubMedCrossRef Coppen EM, van der Grond J, Hart EP, Lakke E, Roos RAC (2018b) The visual cortex and visual cognition in Huntington’s disease: an overview of current literature. Behav Brain Res 351:63–74PubMedCrossRef
Zurück zum Zitat Corey-Bloom J, Williams ME, Beltran-Najera I, Mustafa AI, Snell CM, Castleton J, Smith H, Wright B, Gilbert PE (2020) Central cognitive processing speed is an early marker of Huntington’s disease onset. Mov Disord Clin Pract 8:100–105PubMedPubMedCentralCrossRef Corey-Bloom J, Williams ME, Beltran-Najera I, Mustafa AI, Snell CM, Castleton J, Smith H, Wright B, Gilbert PE (2020) Central cognitive processing speed is an early marker of Huntington’s disease onset. Mov Disord Clin Pract 8:100–105PubMedPubMedCentralCrossRef
Zurück zum Zitat Cummings DM, Milnerwood AJ, Dallérac GM, Vatsavayai SC, Hirst MC, Murphy KP (2007) Abnormal cortical synaptic plasticity in a mouse model of Huntington’s disease. Brain Res Bull 72:103–107PubMedCrossRef Cummings DM, Milnerwood AJ, Dallérac GM, Vatsavayai SC, Hirst MC, Murphy KP (2007) Abnormal cortical synaptic plasticity in a mouse model of Huntington’s disease. Brain Res Bull 72:103–107PubMedCrossRef
Zurück zum Zitat Davis MY, Keene CD, Jayadev S, Bird T (2014) The co-occurrence of Alzheimer’s disease and Huntington’s disease: a neuropathological study of 15 elderly Huntington’s disease subjects. J Huntingtons Dis 3:209–217PubMedCrossRef Davis MY, Keene CD, Jayadev S, Bird T (2014) The co-occurrence of Alzheimer’s disease and Huntington’s disease: a neuropathological study of 15 elderly Huntington’s disease subjects. J Huntingtons Dis 3:209–217PubMedCrossRef
Zurück zum Zitat DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA (2004) Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 33:517–533PubMedCrossRef DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA (2004) Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 33:517–533PubMedCrossRef
Zurück zum Zitat Domínguez DJ, Poudel G, Stout JC, Gray M, Chua P, Borowsky B, Egan GF, Georgiou-Karistianis N (2017) Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington’s disease: 30 months IMAGE-HD data. Cortex 92:139–149CrossRef Domínguez DJ, Poudel G, Stout JC, Gray M, Chua P, Borowsky B, Egan GF, Georgiou-Karistianis N (2017) Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington’s disease: 30 months IMAGE-HD data. Cortex 92:139–149CrossRef
Zurück zum Zitat Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL (2010) Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75:500–507PubMedPubMedCentralCrossRef Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL (2010) Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75:500–507PubMedPubMedCentralCrossRef
Zurück zum Zitat Dumas EM, Say MJ, Jones R, Labuschagne I, O’Regan AM, Hart EP, van den Bogaard SJ, Queller S, Justo D, Coleman A, Dar Santos RC, Dürr A, Leavitt BR, Tabrizi SJ, Roos RA, Stout JC (2012a) Visual working memory impairment in premanifest gene-carriers and early Huntington’s disease. J Huntingtons Dis 1:97–106PubMedCrossRef Dumas EM, Say MJ, Jones R, Labuschagne I, O’Regan AM, Hart EP, van den Bogaard SJ, Queller S, Justo D, Coleman A, Dar Santos RC, Dürr A, Leavitt BR, Tabrizi SJ, Roos RA, Stout JC (2012a) Visual working memory impairment in premanifest gene-carriers and early Huntington’s disease. J Huntingtons Dis 1:97–106PubMedCrossRef
Zurück zum Zitat Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, Hicks SL, Kennard C, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA (2012b) Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington’s disease. Hum Brain Mapp 33:203–212PubMedCrossRef Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, Hicks SL, Kennard C, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA (2012b) Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington’s disease. Hum Brain Mapp 33:203–212PubMedCrossRef
Zurück zum Zitat Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA (2013) A review of cognition in Huntington’s disease. Front Biosci (Schol Ed) 5:1–18PubMedCrossRef Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA (2013) A review of cognition in Huntington’s disease. Front Biosci (Schol Ed) 5:1–18PubMedCrossRef
Zurück zum Zitat Duyckaerts C, Joyon N, Dürr A (2014) Neurodegenerative diseases linked to trinucleotide repeats. In: Kovacs G (ed) Neuropathology of Neurodegenerative diseases: a practical guide. Cambridge University Press Cambridge, pp 195–208CrossRef Duyckaerts C, Joyon N, Dürr A (2014) Neurodegenerative diseases linked to trinucleotide repeats. In: Kovacs G (ed) Neuropathology of Neurodegenerative diseases: a practical guide. Cambridge University Press Cambridge, pp 195–208CrossRef
Zurück zum Zitat Espina M, Di Franco N, Brañas-Navarro M, Navarro IR, Brito V, Lopez-Molina L, Costas-Insua C, Guzmán M, Ginés S (2023) The GRP78-PERK axis contributes to memory and synaptic impairments in Huntington’s disease R6/1 mice. Neurobiol Dis 184:106225PubMedCrossRef Espina M, Di Franco N, Brañas-Navarro M, Navarro IR, Brito V, Lopez-Molina L, Costas-Insua C, Guzmán M, Ginés S (2023) The GRP78-PERK axis contributes to memory and synaptic impairments in Huntington’s disease R6/1 mice. Neurobiol Dis 184:106225PubMedCrossRef
Zurück zum Zitat Fernández-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, Hernández F, Avila J, Lucas JJ (2014) Huntington’s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20:881–885PubMedCrossRef Fernández-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, Hernández F, Avila J, Lucas JJ (2014) Huntington’s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20:881–885PubMedCrossRef
Zurück zum Zitat Fink KD, Rossignol J, Crane AT, Davis KK, Bavar AM, Dekorver NW, Lowrance SA, Reilly MP, Sandstrom MI, von Hörsten S, Lescaudron L, Dunbar GL (2012) Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington’s disease. Behav Neurosci 126:479–487PubMedCrossRef Fink KD, Rossignol J, Crane AT, Davis KK, Bavar AM, Dekorver NW, Lowrance SA, Reilly MP, Sandstrom MI, von Hörsten S, Lescaudron L, Dunbar GL (2012) Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington’s disease. Behav Neurosci 126:479–487PubMedCrossRef
Zurück zum Zitat Gabery S, Kwa JE, Cheong RY, Baldo B, Ferrari Bardile C, Tan B, McLean C, Georgiou-Karistianis N, Poudel GR, Halliday G, Pouladi MA, Petersén Å (2021) Early white matter pathology in the fornix of the limbic system in Huntington disease. Acta Neuropathol 142:791–806PubMedPubMedCentralCrossRef Gabery S, Kwa JE, Cheong RY, Baldo B, Ferrari Bardile C, Tan B, McLean C, Georgiou-Karistianis N, Poudel GR, Halliday G, Pouladi MA, Petersén Å (2021) Early white matter pathology in the fornix of the limbic system in Huntington disease. Acta Neuropathol 142:791–806PubMedPubMedCentralCrossRef
Zurück zum Zitat Giralt A, Saavedra A, Alberch J, Pérez-Navarro E (2012) Cognitive dysfunction in Huntington’s disease: humans, mouse models and molecular mechanisms. J Huntingtons Dis 1:155–173PubMedCrossRef Giralt A, Saavedra A, Alberch J, Pérez-Navarro E (2012) Cognitive dysfunction in Huntington’s disease: humans, mouse models and molecular mechanisms. J Huntingtons Dis 1:155–173PubMedCrossRef
Zurück zum Zitat Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER, Heatwole CR (2020) Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology 94:e2045–e2053PubMedCrossRef Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER, Heatwole CR (2020) Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology 94:e2045–e2053PubMedCrossRef
Zurück zum Zitat Glikmann-Johnston Y, Mercieca EC, Carmichael AM, Alexander B, Harding IH, Stout JC (2021) Hippocampal and striatal volumes correlate with spatial memory impairment in Huntington’s disease. J Neurosci Res 99:2948–2963PubMedCrossRef Glikmann-Johnston Y, Mercieca EC, Carmichael AM, Alexander B, Harding IH, Stout JC (2021) Hippocampal and striatal volumes correlate with spatial memory impairment in Huntington’s disease. J Neurosci Res 99:2948–2963PubMedCrossRef
Zurück zum Zitat Gómez-Tortosa E, del Barrio A, García Ruiz PJ, Pernaute RS, Benítez J, Barroso A, Jiménez FJ, García Yébenes J (1998) Severity of cognitive impairment in juvenile and late-onset Huntington disease. Arch Neurol 55:835–843PubMedCrossRef Gómez-Tortosa E, del Barrio A, García Ruiz PJ, Pernaute RS, Benítez J, Barroso A, Jiménez FJ, García Yébenes J (1998) Severity of cognitive impairment in juvenile and late-onset Huntington disease. Arch Neurol 55:835–843PubMedCrossRef
Zurück zum Zitat Gratuze M, Cisbani G, Cicchetti F, Planel E (2016) Is Huntington’s disease a tauopathy? Brain 139:1014–1025PubMedCrossRef Gratuze M, Cisbani G, Cicchetti F, Planel E (2016) Is Huntington’s disease a tauopathy? Brain 139:1014–1025PubMedCrossRef
Zurück zum Zitat Gregory S, Scahill RI (2018) Functional magnetic resonance imaging in Huntington’s disease. Int Rev Neurobiol 142:381–408PubMedCrossRef Gregory S, Scahill RI (2018) Functional magnetic resonance imaging in Huntington’s disease. Int Rev Neurobiol 142:381–408PubMedCrossRef
Zurück zum Zitat Grosso Jasutkar H, Yamamoto A (2021) Do changes in synaptic autophagy underlie the cognitive impairments in Huntington’s disease? J Huntingtons Dis 10:227–238PubMedPubMedCentralCrossRef Grosso Jasutkar H, Yamamoto A (2021) Do changes in synaptic autophagy underlie the cognitive impairments in Huntington’s disease? J Huntingtons Dis 10:227–238PubMedPubMedCentralCrossRef
Zurück zum Zitat Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr, Schwarcz R, Tagle DA (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 169:340–350PubMedCrossRef Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr, Schwarcz R, Tagle DA (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 169:340–350PubMedCrossRef
Zurück zum Zitat Harrington DL, Rubinov M, Durgerian S, Mourany L, Reece C, Koenig K, Bullmore E, Long JD, Paulsen JS, Rao SM (2015) Network topology and functional connectivity disturbances precede the onset of Huntington’s disease. Brain 138:2332–2346PubMedPubMedCentralCrossRef Harrington DL, Rubinov M, Durgerian S, Mourany L, Reece C, Koenig K, Bullmore E, Long JD, Paulsen JS, Rao SM (2015) Network topology and functional connectivity disturbances precede the onset of Huntington’s disease. Brain 138:2332–2346PubMedPubMedCentralCrossRef
Zurück zum Zitat Harris KL, Armstrong M, Swain R, Erzinclioglu S, Das T, Burgess N, Barker RA, Mason SL (2019) Huntington’s disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory. Cortex 119:417–427PubMedCrossRef Harris KL, Armstrong M, Swain R, Erzinclioglu S, Das T, Burgess N, Barker RA, Mason SL (2019) Huntington’s disease patients display progressive deficits in hippocampal-dependent cognition during a task of spatial memory. Cortex 119:417–427PubMedCrossRef
Zurück zum Zitat Hart EP, Dumas EM, Giltay EJ, Middelkoop HA, Roos RA (2013) Cognition in Huntington’s disease in manifest, premanifest and converting gene carriers over ten years. J Huntingtons Dis 2:137–147PubMedCrossRef Hart EP, Dumas EM, Giltay EJ, Middelkoop HA, Roos RA (2013) Cognition in Huntington’s disease in manifest, premanifest and converting gene carriers over ten years. J Huntingtons Dis 2:137–147PubMedCrossRef
Zurück zum Zitat Hewitt SR, White AJ, Mason SL, Barker RA (2022) Metacognitive insight into cognitive performance in Huntington’s disease gene carriers. BMJ Neurol Open 4:e000268PubMedPubMedCentralCrossRef Hewitt SR, White AJ, Mason SL, Barker RA (2022) Metacognitive insight into cognitive performance in Huntington’s disease gene carriers. BMJ Neurol Open 4:e000268PubMedPubMedCentralCrossRef
Zurück zum Zitat Horta-Barba A, Martínez-Horta S, Pérez-Pérez J, Sampedro F, Puig-Davi A, Pagonabarraga J, Kulisevsky J (2022) Measuring the functional impact of cognitive impairment in Huntington’s disease. J Neurol 269:3541–3549PubMedPubMedCentralCrossRef Horta-Barba A, Martínez-Horta S, Pérez-Pérez J, Sampedro F, Puig-Davi A, Pagonabarraga J, Kulisevsky J (2022) Measuring the functional impact of cognitive impairment in Huntington’s disease. J Neurol 269:3541–3549PubMedPubMedCentralCrossRef
Zurück zum Zitat Horta-Barba A, Martinez-Horta S, Pérez-Pérez J, Puig-Davi A, de Lucia N, de Michele G, Salvatore E, Kehrer S, Priller J, Migliore S, Squitieri F, Castaldo A, Mariotti C, Mañanes V, Lopez-Sendon JL, Rodriguez N, Martinez-Descals A, Júlio F, Januário C, Delussi M, de Tommaso M, Noguera S, Ruiz-Idiago J, Sitek EJ, Wallner R, Nuzzi A, Pagonabarraga J, Kulisevsky J (2023a) Measuring cognitive impairment and monitoring cognitive decline in Huntington’s disease: a comparison of assessment instruments. J Neurol 270:5408–5417PubMedPubMedCentralCrossRef Horta-Barba A, Martinez-Horta S, Pérez-Pérez J, Puig-Davi A, de Lucia N, de Michele G, Salvatore E, Kehrer S, Priller J, Migliore S, Squitieri F, Castaldo A, Mariotti C, Mañanes V, Lopez-Sendon JL, Rodriguez N, Martinez-Descals A, Júlio F, Januário C, Delussi M, de Tommaso M, Noguera S, Ruiz-Idiago J, Sitek EJ, Wallner R, Nuzzi A, Pagonabarraga J, Kulisevsky J (2023a) Measuring cognitive impairment and monitoring cognitive decline in Huntington’s disease: a comparison of assessment instruments. J Neurol 270:5408–5417PubMedPubMedCentralCrossRef
Zurück zum Zitat Horta-Barba A, Martinez-Horta S, Sampedro F, Pérez-Pérez J, Camacho V, Pagonabarraga J, Kulisevsky J (2023b) Structural and metabolic brain correlates of arithmetic word-problem solving in Huntington’s disease. J Neurosci Res 101:990–999PubMedCrossRef Horta-Barba A, Martinez-Horta S, Sampedro F, Pérez-Pérez J, Camacho V, Pagonabarraga J, Kulisevsky J (2023b) Structural and metabolic brain correlates of arithmetic word-problem solving in Huntington’s disease. J Neurosci Res 101:990–999PubMedCrossRef
Zurück zum Zitat Huntington G (1872) On chorea. Med Surg Reporter 26:317–321 Huntington G (1872) On chorea. Med Surg Reporter 26:317–321
Zurück zum Zitat Hwang YS, Oh E, Kim M, Lee CY, Kim HS, Chung SJ, Sung YH, Yoon WT, Cho JH, Lee JH, Kim HJ, Chang HJ, Jeon B, Woo KA, Ko SB, Kwon KY, Moon J, Shin C, Kim YE, Lee JY (2023) Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington’s disease: Korean cohort data. J Neurol Sci 452:120744PubMedCrossRef Hwang YS, Oh E, Kim M, Lee CY, Kim HS, Chung SJ, Sung YH, Yoon WT, Cho JH, Lee JH, Kim HJ, Chang HJ, Jeon B, Woo KA, Ko SB, Kwon KY, Moon J, Shin C, Kim YE, Lee JY (2023) Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington’s disease: Korean cohort data. J Neurol Sci 452:120744PubMedCrossRef
Zurück zum Zitat Jellinger KA (1998) Alzheimer-type lesions in Huntington’s disease. J Neural Transm 105:787–799PubMedCrossRef Jellinger KA (1998) Alzheimer-type lesions in Huntington’s disease. J Neural Transm 105:787–799PubMedCrossRef
Zurück zum Zitat Jellinger KA (2013) Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J Neural Transm 120:157–167PubMedCrossRef Jellinger KA (2013) Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J Neural Transm 120:157–167PubMedCrossRef
Zurück zum Zitat Jellinger KA (2022) Morphological basis of Parkinson disease-associated cognitive impairment: an update. J Neural Transm 129:977–999PubMedCrossRef Jellinger KA (2022) Morphological basis of Parkinson disease-associated cognitive impairment: an update. J Neural Transm 129:977–999PubMedCrossRef
Zurück zum Zitat Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, Reilmann R, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI (2015) The impact of occipital lobe cortical thickness on cognitive task performance: an investigation in Huntington’s disease. Neuropsychologia 79:138–146PubMedCrossRef Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, Reilmann R, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI (2015) The impact of occipital lobe cortical thickness on cognitive task performance: an investigation in Huntington’s disease. Neuropsychologia 79:138–146PubMedCrossRef
Zurück zum Zitat Julayanont P, McFarland NR, Heilman KM (2020) Mild cognitive impairment and dementia in motor manifest Huntington’s disease: classification and prevalence. J Neurol Sci 408:116523PubMedCrossRef Julayanont P, McFarland NR, Heilman KM (2020) Mild cognitive impairment and dementia in motor manifest Huntington’s disease: classification and prevalence. J Neurol Sci 408:116523PubMedCrossRef
Zurück zum Zitat Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB (2005) Thalamic atrophy in Huntington’s disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 15:846–853PubMedCrossRef Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB (2005) Thalamic atrophy in Huntington’s disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 15:846–853PubMedCrossRef
Zurück zum Zitat Kiesmann M, Chanson JB, Godet J, Vogel T, Schweiger L, Chayer S, Kaltenbach G (2013) The movement disorders society criteria for the diagnosis of Parkinson’s disease dementia: their usefulness and limitations in elderly patients. J Neurol 260:2569–2579PubMedCrossRef Kiesmann M, Chanson JB, Godet J, Vogel T, Schweiger L, Chayer S, Kaltenbach G (2013) The movement disorders society criteria for the diagnosis of Parkinson’s disease dementia: their usefulness and limitations in elderly patients. J Neurol 260:2569–2579PubMedCrossRef
Zurück zum Zitat Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA (2005) Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 76:650–655PubMedPubMedCentralCrossRef Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA (2005) Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 76:650–655PubMedPubMedCentralCrossRef
Zurück zum Zitat Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington’s disease transgenic mice. J Neurophysiol 86:2667–2677PubMedCrossRef Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington’s disease transgenic mice. J Neurophysiol 86:2667–2677PubMedCrossRef
Zurück zum Zitat Knox MG, Adler CH, Shill HA, Driver-Dunckley E, Mehta SA, Belden C, Zamrini E, Serrano G, Sabbagh MN, Caviness JN, Sue LI, Davis KJ, Dugger BN, Beach TG (2020) Neuropathological findings in Parkinson’s disease with mild cognitive impairment. Mov Disord 35:845–850PubMedCrossRef Knox MG, Adler CH, Shill HA, Driver-Dunckley E, Mehta SA, Belden C, Zamrini E, Serrano G, Sabbagh MN, Caviness JN, Sue LI, Davis KJ, Dugger BN, Beach TG (2020) Neuropathological findings in Parkinson’s disease with mild cognitive impairment. Mov Disord 35:845–850PubMedCrossRef
Zurück zum Zitat Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA (2014) Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. PLoS ONE 9:e94562PubMedPubMedCentralCrossRef Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA (2014) Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. PLoS ONE 9:e94562PubMedPubMedCentralCrossRef
Zurück zum Zitat Kumar P, Kalonia H, Kumar A (2010) Huntington’s disease: pathogenesis to animal models. Pharmacol Rep 62:1–14PubMedCrossRef Kumar P, Kalonia H, Kumar A (2010) Huntington’s disease: pathogenesis to animal models. Pharmacol Rep 62:1–14PubMedCrossRef
Zurück zum Zitat Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O’Regan A, Queller S, Frost C, Leavitt BR, Dürr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC (2016) Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington’s disease. J Int Neuropsychol Soc 22:595–608PubMedCrossRef Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O’Regan A, Queller S, Frost C, Leavitt BR, Dürr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC (2016) Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington’s disease. J Int Neuropsychol Soc 22:595–608PubMedCrossRef
Zurück zum Zitat Lahr J, Minkova L, Tabrizi SJ, Stout JC, Klöppel S, Scheller E (2018) Working memory-related effective connectivity in huntington’s disease patients. Front Neurol 9:370PubMedPubMedCentralCrossRef Lahr J, Minkova L, Tabrizi SJ, Stout JC, Klöppel S, Scheller E (2018) Working memory-related effective connectivity in huntington’s disease patients. Front Neurol 9:370PubMedPubMedCentralCrossRef
Zurück zum Zitat Langley C, Gregory S, Osborne-Crowley K, O’Callaghan C, Zeun P, Lowe J, Johnson EB, Papoutsi M, Scahill RI, Rees G, Tabrizi SJ, Robbins TW, Sahakian BJ (2021) Fronto-striatal circuits for cognitive flexibility in far from onset Huntington’s disease: evidence from the young adult study. J Neurol Neurosurg Psychiatry 92:143–149PubMedCrossRef Langley C, Gregory S, Osborne-Crowley K, O’Callaghan C, Zeun P, Lowe J, Johnson EB, Papoutsi M, Scahill RI, Rees G, Tabrizi SJ, Robbins TW, Sahakian BJ (2021) Fronto-striatal circuits for cognitive flexibility in far from onset Huntington’s disease: evidence from the young adult study. J Neurol Neurosurg Psychiatry 92:143–149PubMedCrossRef
Zurück zum Zitat Li XY, Xie JJ, Wang JH, Bao YF, Dong Y, Gao B, Shen T, Huang PY, Ying HC, Xu H, Roe AW, Lai HY, Wu ZY (2023) Perivascular spaces relate to the course and cognition of Huntington’s disease. Transl Neurodegener 12:30PubMedPubMedCentralCrossRef Li XY, Xie JJ, Wang JH, Bao YF, Dong Y, Gao B, Shen T, Huang PY, Ying HC, Xu H, Roe AW, Lai HY, Wu ZY (2023) Perivascular spaces relate to the course and cognition of Huntington’s disease. Transl Neurodegener 12:30PubMedPubMedCentralCrossRef
Zurück zum Zitat Liu P, Smith BR, Huang ES, Mahesh A, Vonsattel JPG, Petersen AJ, Gomez-Pastor R, Ashe KH (2019) A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington’s disease patients. Acta Neuropathol Commun 7:111PubMedPubMedCentralCrossRef Liu P, Smith BR, Huang ES, Mahesh A, Vonsattel JPG, Petersen AJ, Gomez-Pastor R, Ashe KH (2019) A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington’s disease patients. Acta Neuropathol Commun 7:111PubMedPubMedCentralCrossRef
Zurück zum Zitat Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Pagonabarraga J, Gomez-Anson B, Kulisevsky J (2020) Structural brain correlates of dementia in Huntington’s disease. Neuroimage Clin 28:102415PubMedPubMedCentralCrossRef Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Pagonabarraga J, Gomez-Anson B, Kulisevsky J (2020) Structural brain correlates of dementia in Huntington’s disease. Neuroimage Clin 28:102415PubMedPubMedCentralCrossRef
Zurück zum Zitat Martínez-Lazcano JC, González-Guevara E, Boll C, Cárdenas G (2022) Gut dysbiosis and homocysteine: a couple for boosting neurotoxicity in Huntington disease. Rev Neurosci 33:819–827PubMedCrossRef Martínez-Lazcano JC, González-Guevara E, Boll C, Cárdenas G (2022) Gut dysbiosis and homocysteine: a couple for boosting neurotoxicity in Huntington disease. Rev Neurosci 33:819–827PubMedCrossRef
Zurück zum Zitat McAllister B, Gusella JF, Landwehrmeyer GB, Lee JM, MacDonald ME, Orth M, Rosser AE, Williams NM, Holmans P, Jones L, Massey TH (2021) Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. Neurology 96:e2395–e2406PubMedPubMedCentralCrossRef McAllister B, Gusella JF, Landwehrmeyer GB, Lee JM, MacDonald ME, Orth M, Rosser AE, Williams NM, Holmans P, Jones L, Massey TH (2021) Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. Neurology 96:e2395–e2406PubMedPubMedCentralCrossRef
Zurück zum Zitat McColgan P, Gregory S, Seunarine KK, Razi A, Papoutsi M, Johnson E, Durr A, Roos RAC, Leavitt BR, Holmans P, Scahill RI, Clark CA, Rees G, Tabrizi SJ (2018) Brain regions showing white matter loss in Huntington’s disease are enriched for synaptic and metabolic genes. Biol Psychiatry 83:456–465PubMedPubMedCentralCrossRef McColgan P, Gregory S, Seunarine KK, Razi A, Papoutsi M, Johnson E, Durr A, Roos RAC, Leavitt BR, Holmans P, Scahill RI, Clark CA, Rees G, Tabrizi SJ (2018) Brain regions showing white matter loss in Huntington’s disease are enriched for synaptic and metabolic genes. Biol Psychiatry 83:456–465PubMedPubMedCentralCrossRef
Zurück zum Zitat McIntosh GC, Jameson HD, Markesbery WR (1978) Huntington disease associated with Alzheimer disease. Ann Neurol 3:545–548PubMedCrossRef McIntosh GC, Jameson HD, Markesbery WR (1978) Huntington disease associated with Alzheimer disease. Ann Neurol 3:545–548PubMedCrossRef
Zurück zum Zitat Mees I, Nisbet RM, Hannan AJ, Renoir T (2023) Implications of tau dysregulation in Huntington’s disease and potential for new therapeutics. J Huntingtons Dis 12:1–13PubMedPubMedCentralCrossRef Mees I, Nisbet RM, Hannan AJ, Renoir T (2023) Implications of tau dysregulation in Huntington’s disease and potential for new therapeutics. J Huntingtons Dis 12:1–13PubMedPubMedCentralCrossRef
Zurück zum Zitat Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P (2018) Rating scales for cognition in Huntington’s disease: critique and recommendations. Mov Disord 33:187–195PubMedCrossRef Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P (2018) Rating scales for cognition in Huntington’s disease: critique and recommendations. Mov Disord 33:187–195PubMedCrossRef
Zurück zum Zitat Migliore S, D’Aurizio G, Scaricamazza E, Maffi S, Ceccarelli C, Ristori G, Romano S, Castaldo A, Fichera M, Curcio G, Squitieri F (2022) Cognitive reserve in early manifest Huntington disease patients: leisure time is associated with lower cognitive and functional impairment. J Pers Med 12:36PubMedPubMedCentralCrossRef Migliore S, D’Aurizio G, Scaricamazza E, Maffi S, Ceccarelli C, Ristori G, Romano S, Castaldo A, Fichera M, Curcio G, Squitieri F (2022) Cognitive reserve in early manifest Huntington disease patients: leisure time is associated with lower cognitive and functional impairment. J Pers Med 12:36PubMedPubMedCentralCrossRef
Zurück zum Zitat Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron 65:178–190PubMedCrossRef Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron 65:178–190PubMedCrossRef
Zurück zum Zitat Montoya A, Price BH, Menear M, Lepage M (2006) Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci 31:21–29PubMedPubMedCentral Montoya A, Price BH, Menear M, Lepage M (2006) Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci 31:21–29PubMedPubMedCentral
Zurück zum Zitat Mörkl S, Müller NJ, Blesl C, Wilkinson L, Tmava A, Wurm W, Holl AK, Painold A (2016) Problem solving, impulse control and planning in patients with early- and late-stage Huntington’s disease. Eur Arch Psychiatry Clin Neurosci 266:663–671PubMedPubMedCentralCrossRef Mörkl S, Müller NJ, Blesl C, Wilkinson L, Tmava A, Wurm W, Holl AK, Painold A (2016) Problem solving, impulse control and planning in patients with early- and late-stage Huntington’s disease. Eur Arch Psychiatry Clin Neurosci 266:663–671PubMedPubMedCentralCrossRef
Zurück zum Zitat Morton AJ, Faull RL, Edwardson JM (2001) Abnormalities in the synaptic vesicle fusion machinery in Huntington’s disease. Brain Res Bull 56:111–117PubMedCrossRef Morton AJ, Faull RL, Edwardson JM (2001) Abnormalities in the synaptic vesicle fusion machinery in Huntington’s disease. Brain Res Bull 56:111–117PubMedCrossRef
Zurück zum Zitat Moss RJ, Mastri AR, Schut LJ (1988) The coexistence and differentiation of late onset Huntington’s disease and Alzheimer’s disease. A case report and review of the literature. J Am Geriatr Soc 36:237–241PubMedCrossRef Moss RJ, Mastri AR, Schut LJ (1988) The coexistence and differentiation of late onset Huntington’s disease and Alzheimer’s disease. A case report and review of the literature. J Am Geriatr Soc 36:237–241PubMedCrossRef
Zurück zum Zitat Myers RH, Sax DS, Schoenfeld M, Bird ED, Wolf PA, Vonsattel JP, White RF, Martin JB (1985) Late onset of Huntington’s disease. J Neurol Neurosurg Psychiatry 48:530–534PubMedPubMedCentralCrossRef Myers RH, Sax DS, Schoenfeld M, Bird ED, Wolf PA, Vonsattel JP, White RF, Martin JB (1985) Late onset of Huntington’s disease. J Neurol Neurosurg Psychiatry 48:530–534PubMedPubMedCentralCrossRef
Zurück zum Zitat Nanetti L, Contarino VE, Castaldo A, Sarro L, Bachoud-Levi AC, Giavazzi M, Frittoli S, Ciammola A, Rizzo E, Gellera C, Bruzzone MG, Taroni F, Grisoli M, Mariotti C (2018) Cortical thickness, stance control, and arithmetic skill: an exploratory study in premanifest Huntington disease. Parkinsonism Relat Disord 51:17–23PubMedCrossRef Nanetti L, Contarino VE, Castaldo A, Sarro L, Bachoud-Levi AC, Giavazzi M, Frittoli S, Ciammola A, Rizzo E, Gellera C, Bruzzone MG, Taroni F, Grisoli M, Mariotti C (2018) Cortical thickness, stance control, and arithmetic skill: an exploratory study in premanifest Huntington disease. Parkinsonism Relat Disord 51:17–23PubMedCrossRef
Zurück zum Zitat Nithianantharajah J, Hannan AJ (2013) Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington’s disease. Neuroscience 251:66–74PubMedCrossRef Nithianantharajah J, Hannan AJ (2013) Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington’s disease. Neuroscience 251:66–74PubMedCrossRef
Zurück zum Zitat Padron-Rivera G, Romero-Molina AO, Diaz R, Vaca-Palomares I, Ochoa-Morales A, Romero-Rebollar C, Chirino-Pérez A, Fernandez-Ruiz J (2022) Frontostriatal circuits alterations associated with cognitive flexibility deterioration in Huntington’s disease. Neurodegener Dis 22:24–28PubMedCrossRef Padron-Rivera G, Romero-Molina AO, Diaz R, Vaca-Palomares I, Ochoa-Morales A, Romero-Rebollar C, Chirino-Pérez A, Fernandez-Ruiz J (2022) Frontostriatal circuits alterations associated with cognitive flexibility deterioration in Huntington’s disease. Neurodegener Dis 22:24–28PubMedCrossRef
Zurück zum Zitat Papoutsi M, Flower M, Hensman Moss DJ, Holmans P, Estevez-Fraga C, Johnson EB, Scahill RI, Rees G, Langbehn D, Tabrizi SJ (2022) Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington’s disease. Brain Commun 4:fcac279PubMedPubMedCentralCrossRef Papoutsi M, Flower M, Hensman Moss DJ, Holmans P, Estevez-Fraga C, Johnson EB, Scahill RI, Rees G, Langbehn D, Tabrizi SJ (2022) Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington’s disease. Brain Commun 4:fcac279PubMedPubMedCentralCrossRef
Zurück zum Zitat Papp KV, Kaplan RF, Snyder PJ (2011) Biological markers of cognition in prodromal Huntington’s disease: a review. Brain Cogn 77:280–291PubMedCrossRef Papp KV, Kaplan RF, Snyder PJ (2011) Biological markers of cognition in prodromal Huntington’s disease: a review. Brain Cogn 77:280–291PubMedCrossRef
Zurück zum Zitat Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC (2006) Brain structure in preclinical Huntington’s disease. Biol Psychiatry 59:57–63PubMedCrossRef Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC (2006) Brain structure in preclinical Huntington’s disease. Biol Psychiatry 59:57–63PubMedCrossRef
Zurück zum Zitat Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) Detection of Huntington’s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880PubMedCrossRef Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) Detection of Huntington’s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880PubMedCrossRef
Zurück zum Zitat Paulsen JS, Miller AC, Hayes T, Shaw E (2017) Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 144:69–91PubMedCrossRef Paulsen JS, Miller AC, Hayes T, Shaw E (2017) Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 144:69–91PubMedCrossRef
Zurück zum Zitat Pedersen KF, Larsen JP, Tysnes OB, Alves G (2017) Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study. Neurology 88:767–774PubMedCrossRef Pedersen KF, Larsen JP, Tysnes OB, Alves G (2017) Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study. Neurology 88:767–774PubMedCrossRef
Zurück zum Zitat Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J (2005) Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 239:11–19PubMedCrossRef Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J (2005) Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 239:11–19PubMedCrossRef
Zurück zum Zitat Peng C, Zhu G, Liu X, Li H (2018) Mutant Huntingtin causes a selective decrease in the expression of synaptic vesicle protein 2C. Neurosci Bull 34:747–758PubMedPubMedCentralCrossRef Peng C, Zhu G, Liu X, Li H (2018) Mutant Huntingtin causes a selective decrease in the expression of synaptic vesicle protein 2C. Neurosci Bull 34:747–758PubMedPubMedCentralCrossRef
Zurück zum Zitat Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308PubMedCrossRef Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308PubMedCrossRef
Zurück zum Zitat Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992PubMedCrossRef Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992PubMedCrossRef
Zurück zum Zitat Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr (2009) Mild cognitive impairment: ten years later. Arch Neurol 66:1447–1455PubMedPubMedCentralCrossRef Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr (2009) Mild cognitive impairment: ten years later. Arch Neurol 66:1447–1455PubMedPubMedCentralCrossRef
Zurück zum Zitat Petrozziello T, Huntress SS, Castillo-Torres AL, Quinn JP, Connors TR, Auger CA, Mills AN, Kim SE, Liu S, Mahmood F, Boudi A, Wu M, Sapp E, Kivisäkk P, Sunderesh SR, Pouladi MA, Arnold SE, Hyman BT, Rosas HD, DiFiglia M, Mouro Pinto R, Kegel-Gleason K, Sadri-Vakili G (2023) Age-dependent increase in tau phosphorylation at serine 396 in Huntington’s disease prefrontal cortex. J Huntingtons Dis 12:267–281PubMedCrossRef Petrozziello T, Huntress SS, Castillo-Torres AL, Quinn JP, Connors TR, Auger CA, Mills AN, Kim SE, Liu S, Mahmood F, Boudi A, Wu M, Sapp E, Kivisäkk P, Sunderesh SR, Pouladi MA, Arnold SE, Hyman BT, Rosas HD, DiFiglia M, Mouro Pinto R, Kegel-Gleason K, Sadri-Vakili G (2023) Age-dependent increase in tau phosphorylation at serine 396 in Huntington’s disease prefrontal cortex. J Huntingtons Dis 12:267–281PubMedCrossRef
Zurück zum Zitat Petry S, Nateghi B, Keraudren R, Sergeant N, Planel E, Hébert SS, St-Amour I (2023) Differential regulation of tau exon 2 and 10 isoforms in Huntington’s disease brain. Neuroscience 518:54–63PubMedCrossRef Petry S, Nateghi B, Keraudren R, Sergeant N, Planel E, Hébert SS, St-Amour I (2023) Differential regulation of tau exon 2 and 10 isoforms in Huntington’s disease brain. Neuroscience 518:54–63PubMedCrossRef
Zurück zum Zitat Pfalzer AC, Watson KH, Ciriegio AE, Hale L, Diehl S, McDonell KE, Vnencak-Jones C, Huitz E, Snow A, Roth MC, Guthrie CS, Riordan H, Long JD, Compas BE, Claassen DO (2023) Impairments to executive function in emerging adults with Huntington disease. J Neurol Neurosurg Psychiatry 94:130–135PubMedCrossRef Pfalzer AC, Watson KH, Ciriegio AE, Hale L, Diehl S, McDonell KE, Vnencak-Jones C, Huitz E, Snow A, Roth MC, Guthrie CS, Riordan H, Long JD, Compas BE, Claassen DO (2023) Impairments to executive function in emerging adults with Huntington disease. J Neurol Neurosurg Psychiatry 94:130–135PubMedCrossRef
Zurück zum Zitat Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D (2015) Longitudinal study of normal cognition in Parkinson disease. Neurology 85:1276–1282PubMedPubMedCentralCrossRef Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D (2015) Longitudinal study of normal cognition in Parkinson disease. Neurology 85:1276–1282PubMedPubMedCentralCrossRef
Zurück zum Zitat Pini L, Jacquemot C, Cagnin A, Meneghello F, Semenza C, Mantini D, Vallesi A (2020) Aberrant brain network connectivity in presymptomatic and manifest Huntington’s disease: a systematic review. Hum Brain Mapp 41:256–269PubMedCrossRef Pini L, Jacquemot C, Cagnin A, Meneghello F, Semenza C, Mantini D, Vallesi A (2020) Aberrant brain network connectivity in presymptomatic and manifest Huntington’s disease: a systematic review. Hum Brain Mapp 41:256–269PubMedCrossRef
Zurück zum Zitat Poudel GR, Stout JC, Domínguez DJ, Salmon L, Churchyard A, Chua P, Georgiou-Karistianis N, Egan GF (2014) White matter connectivity reflects clinical and cognitive status in Huntington’s disease. Neurobiol Dis 65:180–187PubMedCrossRef Poudel GR, Stout JC, Domínguez DJ, Salmon L, Churchyard A, Chua P, Georgiou-Karistianis N, Egan GF (2014) White matter connectivity reflects clinical and cognitive status in Huntington’s disease. Neurobiol Dis 65:180–187PubMedCrossRef
Zurück zum Zitat Prichard JC (1837) A treatise on insanity and other disorders affecting the mind. Haswell, Barrington, and Haswell, Philadelphia Prichard JC (1837) A treatise on insanity and other disorders affecting the mind. Haswell, Barrington, and Haswell, Philadelphia
Zurück zum Zitat Rangel-Barajas C, Rebec GV (2016) Dysregulation of corticostriatal connectivity in Huntington’s disease: a role for dopamine modulation. J Huntingtons Dis 5:303–331PubMedPubMedCentralCrossRef Rangel-Barajas C, Rebec GV (2016) Dysregulation of corticostriatal connectivity in Huntington’s disease: a role for dopamine modulation. J Huntingtons Dis 5:303–331PubMedPubMedCentralCrossRef
Zurück zum Zitat Ransome MI, Renoir T, Hannan AJ (2012) Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington’s disease. Neural Plast 2012:874387PubMedPubMedCentralCrossRef Ransome MI, Renoir T, Hannan AJ (2012) Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington’s disease. Neural Plast 2012:874387PubMedPubMedCentralCrossRef
Zurück zum Zitat Reyes MG, Gibbons S (1985) Dementia of the Alzheimer’s type and Huntington’s disease. Neurology 35:273–277PubMedCrossRef Reyes MG, Gibbons S (1985) Dementia of the Alzheimer’s type and Huntington’s disease. Neurology 35:273–277PubMedCrossRef
Zurück zum Zitat Rodrigues FB, Byrne L, McColgan P, Robertson N, Tabrizi SJ, Leavitt BR, Zetterberg H, Wild EJ (2016) Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease. J Neurochem 139:22–25PubMedPubMedCentralCrossRef Rodrigues FB, Byrne L, McColgan P, Robertson N, Tabrizi SJ, Leavitt BR, Zetterberg H, Wild EJ (2016) Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease. J Neurochem 139:22–25PubMedPubMedCentralCrossRef
Zurück zum Zitat Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65:745–747PubMedCrossRef Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65:745–747PubMedCrossRef
Zurück zum Zitat Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH (2006) Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 21:1317–1325PubMedCrossRef Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH (2006) Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 21:1317–1325PubMedCrossRef
Zurück zum Zitat Rosas HD, Wilkens P, Salat DH, Mercaldo ND, Vangel M, Yendiki AY, Hersch SM (2018) Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. Neuroimage Clin 20:236–242PubMedPubMedCentralCrossRef Rosas HD, Wilkens P, Salat DH, Mercaldo ND, Vangel M, Yendiki AY, Hersch SM (2018) Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. Neuroimage Clin 20:236–242PubMedPubMedCentralCrossRef
Zurück zum Zitat Rosca EC, Simu M (2022) Montreal cognitive assessment for evaluating cognitive impairment in Huntington’s disease: a systematic review. CNS Spectr 27:27–45PubMedCrossRef Rosca EC, Simu M (2022) Montreal cognitive assessment for evaluating cognitive impairment in Huntington’s disease: a systematic review. CNS Spectr 27:27–45PubMedCrossRef
Zurück zum Zitat Roze E, Cahill E, Martin E, Bonnet C, Vanhoutte P, Betuing S, Caboche J (2011) Huntington’s disease and striatal signaling. Front Neuroanat 5:55PubMedPubMedCentralCrossRef Roze E, Cahill E, Martin E, Bonnet C, Vanhoutte P, Betuing S, Caboche J (2011) Huntington’s disease and striatal signaling. Front Neuroanat 5:55PubMedPubMedCentralCrossRef
Zurück zum Zitat Sampedro F, Martínez-Horta S, Perez-Perez J, Horta-Barba A, Lopez-Mora DA, Camacho V, Fernández-León A, Gomez-Anson B, Carrió I, Kulisevsky J (2019) Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington’s disease. Eur J Nucl Med Mol Imaging 46:1111–1116PubMedCrossRef Sampedro F, Martínez-Horta S, Perez-Perez J, Horta-Barba A, Lopez-Mora DA, Camacho V, Fernández-León A, Gomez-Anson B, Carrió I, Kulisevsky J (2019) Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington’s disease. Eur J Nucl Med Mol Imaging 46:1111–1116PubMedCrossRef
Zurück zum Zitat Sapp E, Seeley C, Iuliano M, Weisman E, Vodicka P, DiFiglia M, Kegel-Gleason KB (2020) Protein changes in synaptosomes of Huntington’s disease knock-in mice are dependent on age and brain region. Neurobiol Dis 141:104950PubMedCrossRef Sapp E, Seeley C, Iuliano M, Weisman E, Vodicka P, DiFiglia M, Kegel-Gleason KB (2020) Protein changes in synaptosomes of Huntington’s disease knock-in mice are dependent on age and brain region. Neurobiol Dis 141:104950PubMedCrossRef
Zurück zum Zitat Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, Lowe J, Nair A, O’Callaghan C, Langley C, Papoutsi M, McColgan P, Estevez-Fraga C, Fayer K, Wellington H, Rodrigues FB, Byrne LM, Heselgrave A, Hyare H, Sampaio C, Zetterberg H, Zhang H, Wild EJ, Rees G, Robbins TW, Sahakian BJ, Langbehn D, Tabrizi SJ (2020) Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease young adult study (HD-YAS): a cross-sectional analysis. Lancet Neurol 19:502–512PubMedPubMedCentralCrossRef Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, Lowe J, Nair A, O’Callaghan C, Langley C, Papoutsi M, McColgan P, Estevez-Fraga C, Fayer K, Wellington H, Rodrigues FB, Byrne LM, Heselgrave A, Hyare H, Sampaio C, Zetterberg H, Zhang H, Wild EJ, Rees G, Robbins TW, Sahakian BJ, Langbehn D, Tabrizi SJ (2020) Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease young adult study (HD-YAS): a cross-sectional analysis. Lancet Neurol 19:502–512PubMedPubMedCentralCrossRef
Zurück zum Zitat Sierra LA, Hughes SB, Ullman CJ, Hall A, Pandeya SR, Schubert R, Frank SA, Halko MA, Corey-Bloom J, Laganiere S (2023a) LASSI-L detects early cognitive changes in pre-motor manifest Huntington’s disease: a replication and validation study. Front Neurol 14:1191718PubMedPubMedCentralCrossRef Sierra LA, Hughes SB, Ullman CJ, Hall A, Pandeya SR, Schubert R, Frank SA, Halko MA, Corey-Bloom J, Laganiere S (2023a) LASSI-L detects early cognitive changes in pre-motor manifest Huntington’s disease: a replication and validation study. Front Neurol 14:1191718PubMedPubMedCentralCrossRef
Zurück zum Zitat Sierra LA, Ullman CJ, Baselga-Garriga C, Pandeya SR, Frank SA, Laganiere S (2023b) Prevalence of neurocognitive disorder in Huntington’s disease using the enroll-HD dataset. Front Neurol 14:1198145PubMedPubMedCentralCrossRef Sierra LA, Ullman CJ, Baselga-Garriga C, Pandeya SR, Frank SA, Laganiere S (2023b) Prevalence of neurocognitive disorder in Huntington’s disease using the enroll-HD dataset. Front Neurol 14:1198145PubMedPubMedCentralCrossRef
Zurück zum Zitat Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS (2012) Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. Neuropsychology 26:664–669PubMedPubMedCentralCrossRef Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS (2012) Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. Neuropsychology 26:664–669PubMedPubMedCentralCrossRef
Zurück zum Zitat Snowden JS (2017) The neuropsychology of Huntington’s disease. Arch Clin Neuropsychol 32:876–887PubMedCrossRef Snowden JS (2017) The neuropsychology of Huntington’s disease. Arch Clin Neuropsychol 32:876–887PubMedCrossRef
Zurück zum Zitat Soloveva MV, Jamadar SD, Poudel G, Georgiou-Karistianis N (2018) A critical review of brain and cognitive reserve in Huntington’s disease. Neurosci Biobehav Rev 88:155–169PubMedCrossRef Soloveva MV, Jamadar SD, Poudel G, Georgiou-Karistianis N (2018) A critical review of brain and cognitive reserve in Huntington’s disease. Neurosci Biobehav Rev 88:155–169PubMedCrossRef
Zurück zum Zitat Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ (2004) Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington’s disease transgenic mice. Eur J Neurosci 19:2799–2807PubMedCrossRef Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ (2004) Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington’s disease transgenic mice. Eur J Neurosci 19:2799–2807PubMedCrossRef
Zurück zum Zitat St-Amour I, Turgeon A, Goupil C, Planel E, Hébert SS (2018) Co-occurrence of mixed proteinopathies in late-stage Huntington’s disease. Acta Neuropathol 135:249–265PubMedCrossRef St-Amour I, Turgeon A, Goupil C, Planel E, Hébert SS (2018) Co-occurrence of mixed proteinopathies in late-stage Huntington’s disease. Acta Neuropathol 135:249–265PubMedCrossRef
Zurück zum Zitat Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH (2011) Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25:1–14PubMedPubMedCentralCrossRef Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH (2011) Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25:1–14PubMedPubMedCentralCrossRef
Zurück zum Zitat Svenningsson P, Westman E, Ballard C, Aarsland D (2012) Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11:697–707PubMedCrossRef Svenningsson P, Westman E, Ballard C, Aarsland D (2012) Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11:697–707PubMedCrossRef
Zurück zum Zitat Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791–801PubMedPubMedCentralCrossRef Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791–801PubMedPubMedCentralCrossRef
Zurück zum Zitat Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC (2011) Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31–42PubMedCrossRef Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC (2011) Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31–42PubMedCrossRef
Zurück zum Zitat Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR (2012) Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42–53PubMedCrossRef Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR (2012) Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42–53PubMedCrossRef
Zurück zum Zitat Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C (2022) A biological classification of Huntington’s disease: the integrated staging system. Lancet Neurol 21:632–644PubMedCrossRef Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C (2022) A biological classification of Huntington’s disease: the integrated staging system. Lancet Neurol 21:632–644PubMedCrossRef
Zurück zum Zitat Tobore TO (2019) Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington’s disease. J Neurosci Res 97:1455–1468PubMedCrossRef Tobore TO (2019) Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington’s disease. J Neurosci Res 97:1455–1468PubMedCrossRef
Zurück zum Zitat Turner K, Bartlett D, Grainger SA, Eddy C, Reyes A, Kordsachia C, Turner M, Stout JC, Georgiou-Karistianis N, Henry JD, Ziman M, Cruickshank T (2022) Profiling social cognition in premanifest Huntington’s disease. J Int Neuropsychol Soc 28:217–229PubMedCrossRef Turner K, Bartlett D, Grainger SA, Eddy C, Reyes A, Kordsachia C, Turner M, Stout JC, Georgiou-Karistianis N, Henry JD, Ziman M, Cruickshank T (2022) Profiling social cognition in premanifest Huntington’s disease. J Int Neuropsychol Soc 28:217–229PubMedCrossRef
Zurück zum Zitat Unmack Larsen I, Vinther-Jensen T, Gade A, Nielsen JE, Vogel A (2015) Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington’s disease gene-expansion carriers. J Int Neuropsychol Soc 21:193–202PubMedCrossRef Unmack Larsen I, Vinther-Jensen T, Gade A, Nielsen JE, Vogel A (2015) Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington’s disease gene-expansion carriers. J Int Neuropsychol Soc 21:193–202PubMedCrossRef
Zurück zum Zitat Unschuld PG, Edden RA, Carass A, Liu X, Shanahan M, Wang X, Oishi K, Brandt J, Bassett SS, Redgrave GW, Margolis RL, van Zijl PC, Barker PB, Ross CA (2012) Brain metabolite alterations and cognitive dysfunction in early Huntington’s disease. Mov Disord 27:895–902PubMedPubMedCentralCrossRef Unschuld PG, Edden RA, Carass A, Liu X, Shanahan M, Wang X, Oishi K, Brandt J, Bassett SS, Redgrave GW, Margolis RL, van Zijl PC, Barker PB, Ross CA (2012) Brain metabolite alterations and cognitive dysfunction in early Huntington’s disease. Mov Disord 27:895–902PubMedPubMedCentralCrossRef
Zurück zum Zitat Unschuld PG, Liu X, Shanahan M, Margolis RL, Bassett SS, Brandt J, Schretlen DJ, Redgrave GW, Hua J, Hock C, Reading SA, van Zijl PC, Pekar JJ, Ross CA (2013) Prefrontal executive function associated coupling relates to Huntington’s disease stage. Cortex 49:2661–2673PubMedCrossRef Unschuld PG, Liu X, Shanahan M, Margolis RL, Bassett SS, Brandt J, Schretlen DJ, Redgrave GW, Hua J, Hock C, Reading SA, van Zijl PC, Pekar JJ, Ross CA (2013) Prefrontal executive function associated coupling relates to Huntington’s disease stage. Cortex 49:2661–2673PubMedCrossRef
Zurück zum Zitat Usdin MT, Shelbourne PF, Myers RM, Madison DV (1999) Impaired synaptic plasticity in mice carrying the Huntington’s disease mutation. Hum Mol Genet 8:839–846PubMedCrossRef Usdin MT, Shelbourne PF, Myers RM, Madison DV (1999) Impaired synaptic plasticity in mice carrying the Huntington’s disease mutation. Hum Mol Genet 8:839–846PubMedCrossRef
Zurück zum Zitat Valdés Hernández MDC, Abu-Hussain J, Qiu X, Priller J, Parra Rodríguez M, Pino M, Báez S, Ibáñez A (2019) Structural neuroimaging differentiates vulnerability from disease manifestation in Colombian families with Huntington’s disease. Brain Behav 9:e01343PubMedPubMedCentralCrossRef Valdés Hernández MDC, Abu-Hussain J, Qiu X, Priller J, Parra Rodríguez M, Pino M, Báez S, Ibáñez A (2019) Structural neuroimaging differentiates vulnerability from disease manifestation in Colombian families with Huntington’s disease. Brain Behav 9:e01343PubMedPubMedCentralCrossRef
Zurück zum Zitat Vidal-Sancho L, Fernández-García S, Solés-Tarrés I, Alberch J, Xifró X (2020) Decreased myocyte enhancer factor 2 levels in the hippocampus of Huntington’s disease mice are related to cognitive dysfunction. Mol Neurobiol 57:4549–4562PubMedCrossRef Vidal-Sancho L, Fernández-García S, Solés-Tarrés I, Alberch J, Xifró X (2020) Decreased myocyte enhancer factor 2 levels in the hippocampus of Huntington’s disease mice are related to cognitive dysfunction. Mol Neurobiol 57:4549–4562PubMedCrossRef
Zurück zum Zitat Vinther-Jensen T, Larsen IU, Hjermind LE, Budtz-Jørgensen E, Nielsen TT, Nørremølle A, Nielsen JE, Vogel A (2014) A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington’s disease. Orphanet J Rare Dis 9:114PubMedPubMedCentralCrossRef Vinther-Jensen T, Larsen IU, Hjermind LE, Budtz-Jørgensen E, Nielsen TT, Nørremølle A, Nielsen JE, Vogel A (2014) A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington’s disease. Orphanet J Rare Dis 9:114PubMedPubMedCentralCrossRef
Zurück zum Zitat Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577PubMedCrossRef Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577PubMedCrossRef
Zurück zum Zitat Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, Spillantini MG, Cicchetti F, Barker RA (2015) The role of tau in the pathological process and clinical expression of Huntington’s disease. Brain 138:1907–1918PubMedPubMedCentralCrossRef Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, Spillantini MG, Cicchetti F, Barker RA (2015) The role of tau in the pathological process and clinical expression of Huntington’s disease. Brain 138:1907–1918PubMedPubMedCentralCrossRef
Zurück zum Zitat Waldvogel HJ, Thu D, Hogg V, Tippett L, Faull RL (2012) Selective neurodegeneration, neuropathology and symptom profiles in Huntington’s disease. Adv Exp Med Biol 769:141–152PubMedCrossRef Waldvogel HJ, Thu D, Hogg V, Tippett L, Faull RL (2012) Selective neurodegeneration, neuropathology and symptom profiles in Huntington’s disease. Adv Exp Med Biol 769:141–152PubMedCrossRef
Zurück zum Zitat Wallace M, Downing N, Lourens S, Mills J, Kim JI, Long J, Paulsen J (2016) Is there an association of physical activity with brain volume, behavior, and day-to-day functioning? A cross sectional design in prodromal and early Huntington disease. PLoS Curr 8:ecurrents.hd.cba6ea74972cf8412a73ce52eb018c1ePubMedPubMedCentral Wallace M, Downing N, Lourens S, Mills J, Kim JI, Long J, Paulsen J (2016) Is there an association of physical activity with brain volume, behavior, and day-to-day functioning? A cross sectional design in prodromal and early Huntington disease. PLoS Curr 8:ecurrents.hd.cba6ea74972cf8412a73ce52eb018c1ePubMedPubMedCentral
Zurück zum Zitat Ward J, Sheppard JM, Shpritz B, Margolis RL, Rosenblatt A, Brandt J (2006) A four-year prospective study of cognitive functioning in Huntington’s disease. J Int Neuropsychol Soc 12:445–454PubMedCrossRef Ward J, Sheppard JM, Shpritz B, Margolis RL, Rosenblatt A, Brandt J (2006) A four-year prospective study of cognitive functioning in Huntington’s disease. J Int Neuropsychol Soc 12:445–454PubMedCrossRef
Zurück zum Zitat Weiss AR, Liguore WA, Brandon K, Wang X, Liu Z, Domire JS, Button D, Srinivasan S, Kroenke CD, McBride JL (2022) A novel rhesus macaque model of Huntington’s disease recapitulates key neuropathological changes along with motor and cognitive decline. Elife 11:e77568PubMedPubMedCentralCrossRef Weiss AR, Liguore WA, Brandon K, Wang X, Liu Z, Domire JS, Button D, Srinivasan S, Kroenke CD, McBride JL (2022) A novel rhesus macaque model of Huntington’s disease recapitulates key neuropathological changes along with motor and cognitive decline. Elife 11:e77568PubMedPubMedCentralCrossRef
Zurück zum Zitat Wilton DK, Mastro K, Heller MD, Gergits FW, Willing CR, Fahey JB, Frouin A, Daggett A, Gu X, Kim YA, Faull RLM, Jayadev S, Yednock T, Yang XW, Stevens B (2023) Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington’s disease. Nat Med 29:2866–2884PubMedPubMedCentralCrossRef Wilton DK, Mastro K, Heller MD, Gergits FW, Willing CR, Fahey JB, Frouin A, Daggett A, Gu X, Kim YA, Faull RLM, Jayadev S, Yednock T, Yang XW, Stevens B (2023) Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington’s disease. Nat Med 29:2866–2884PubMedPubMedCentralCrossRef
Zurück zum Zitat Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment - beyond controversies, towards a consensus: report of the International working group on mild cognitive impairment. J Intern Med 256:240–246PubMedCrossRef Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment - beyond controversies, towards a consensus: report of the International working group on mild cognitive impairment. J Intern Med 256:240–246PubMedCrossRef
Zurück zum Zitat Wolf RC, Sambataro F, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer B (2008a) Altered frontostriatal coupling in pre-manifest Huntington’s disease: effects of increasing cognitive load. Eur J Neurol 15:1180–1190PubMedCrossRef Wolf RC, Sambataro F, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer B (2008a) Altered frontostriatal coupling in pre-manifest Huntington’s disease: effects of increasing cognitive load. Eur J Neurol 15:1180–1190PubMedCrossRef
Zurück zum Zitat Wolf RC, Sambataro F, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer B (2008b) Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington’s disease. Exp Neurol 213:137–144PubMedCrossRef Wolf RC, Sambataro F, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer B (2008b) Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington’s disease. Exp Neurol 213:137–144PubMedCrossRef
Zurück zum Zitat Wolf RC, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer GB (2008c) Functional imaging of cognitive processes in Huntington’s disease and its presymptomatic mutation carriers. Nervenarzt 79:408–420PubMedCrossRef Wolf RC, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer GB (2008c) Functional imaging of cognitive processes in Huntington’s disease and its presymptomatic mutation carriers. Nervenarzt 79:408–420PubMedCrossRef
Zurück zum Zitat Wright DJ, Renoir T, Gray LJ, Hannan AJ (2017) Huntington’s disease: pathogenic mechanisms and therapeutic targets. Adv Neurobiol 15:93–128PubMedCrossRef Wright DJ, Renoir T, Gray LJ, Hannan AJ (2017) Huntington’s disease: pathogenic mechanisms and therapeutic targets. Adv Neurobiol 15:93–128PubMedCrossRef
Zurück zum Zitat Yamamoto A, Yue Z (2014) Autophagy and its normal and pathogenic states in the brain. Annu Rev Neurosci 37:55–78PubMedCrossRef Yamamoto A, Yue Z (2014) Autophagy and its normal and pathogenic states in the brain. Annu Rev Neurosci 37:55–78PubMedCrossRef
Zurück zum Zitat Zhang Y, Zhou J, Gehl CR, Long JD, Johnson H, Magnotta VA, Sewell D, Shannon K, Paulsen JS (2021) Mild cognitive impairment as an early landmark in Huntington’s disease. Front Neurol 12:678652PubMedPubMedCentralCrossRef Zhang Y, Zhou J, Gehl CR, Long JD, Johnson H, Magnotta VA, Sewell D, Shannon K, Paulsen JS (2021) Mild cognitive impairment as an early landmark in Huntington’s disease. Front Neurol 12:678652PubMedPubMedCentralCrossRef
Metadaten
Titel
Mild cognitive impairment in Huntington’s disease: challenges and outlooks
verfasst von
Kurt A. Jellinger
Publikationsdatum
24.01.2024
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 4/2024
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-024-02744-8

Weitere Artikel der Ausgabe 4/2024

Journal of Neural Transmission 4/2024 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Original Article

Somatosensory evoked potentials recorded from DBS electrodes: the origin of subcortical N18

Neurology and Preclinical Neurological Studies - Original Article

Validation of the Italian version of the Parkinson’s Disease- Cognitive Functional Rating Scale

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.